10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Latest (Page 3)
ADT and Heart Failure: New Study Reveals Increased Risk for Prostate Cancer Patients
Meta-analysis finds androgen deprivation therapy linked to higher heart failure risk in prostate cancer patients.
Antibiotics, PPIs, and Probiotics: No Impact on Immunotherapy Outcomes in ES-SCLC
Study finds common medications don't affect immunotherapy efficacy in extensive-stage small cell lung cancer.
Valemetostat Shows Promise in Treating Relapsed/Refractory Peripheral T-Cell Lymphoma
Phase 2 trial of valemetostat demonstrates high response rates in difficult-to-treat lymphoma patients.
Novel Neoadjuvant Chemoradiation Approach Shows Promise for High-Risk Prostate Cancer
Study evaluates docetaxel plus radiotherapy before surgery in high-risk prostate cancer patients
Long-Term Study Confirms T-DM1's Superiority in HER2+ Breast Cancer Treatment
T-DM1 shows significant improvement in overall survival for HER2+ early breast cancer patients.
Durvalumab Boosts Survival in Muscle-Invasive Bladder Cancer: NIAGARA Trial Results
Immunotherapy drug durvalumab improves outcomes for muscle-invasive bladder cancer when added to chemotherapy
Pembrolizumab Boosts Survival in Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Final Results
Pembrolizumab plus chemotherapy improves overall survival in early-stage triple-negative breast cancer.
Cisplatin Schedules in Head and Neck Cancer: Weekly vs Bolus Regimens Show Similar Survival Outcomes
Network meta-analysis finds no significant difference in survival between weekly and bolus cisplatin for head and neck cancer.
Biomarker Breakthrough: TMB and PD-L1 Predict Immunotherapy Success in Advanced Bladder Cancer
Study reveals TMB and PD-L1 as potential biomarkers for immunotherapy response in urothelial carcinoma
Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Promising Combo Therapy Shows High Response Rate in High-Risk Melanoma
New immunotherapy combo shows 55% major pathologic response in high-risk melanoma, activating immune system
Epigenetic-Immunotherapy Combo Shows Promise in Advanced Pancreatic Cancer
Phase 2 trial combines HDAC inhibitor and PD-1 inhibitor in pancreatic cancer, showing durable responses.